This is a big deal for TIL therapy solid tumor indication expansion. Colorectal and breast cancers are two of the most common neoplasms world wide. TAM is enormous if $IOVA’s trial data demonstrates a positive outcome https://x.com/biotechscanner/status/2061412036974719485

This is a big deal for TIL therapy solid tumor indication expansion. Colorectal and breast cancers are two of the most common neoplasms world wide. TAM is enormous if $IOVA’s trial data demonstrates a positive outcome https://x.com/biotechscanner/status/2061412036974719485

$IOVA Right on time! 🗞️ IOV-5001 profoundly strategic given the use of IL-12 instead of IL-2, to begin enrollment in the second half of 2026. Cohorts include advanced colorectal, triple-negative, and estrogen receptor-low breast cancers, as well as other highly prevalent solid tumors representing